Latest Press Releases

Health News Posted on Sunday, December 10, 2017

Press Releases »

New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients

New ZUMA-1 trial data published in The New England Journal of Medicine report long-term measurable remission rates 15 months following treatment with Yescarta™ ...

Read More ...

Primary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

- At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Eric Althoff Novartis Global Media Relations 1-212-830-2408 (office) 1-646-438-4335 (mobile) eric.a...

Read More ...

CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma

Treatments Hold Promise for People with Hard-to-Treat Blood Cancers ATLANTA , Dec. 10, 2017 /PRNewswire-USNewswire/ -- For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American S...

Read More ...

The Emirates Pathology Society (EPS): Earlier Diagnoses of Cancer, Better Survival Rates & Improved Quality of Life Through Next-Generation Sequencing (NGS)

DUBAI , UAE, December 10, 2017 /PRNewswire/ -- The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical genomics are paving the way to novel approaches for the diagnosis, management, and treatment of patients with...

Read More ...

PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017

- At 24 months Ropeginterferon alfa-2b: WALTHAM, Mass. , Dec. 10, 2017 /PRNewswire/ -- PharmaEssentia USA , a subsidiary of PharmaEssentia Corporation (Taipei Exchange: 6446), today announced the latest follow-up results of Ropeginterferon alfa-2b from the ongoing, long-term, follow-up tri...

Read More ...

Medivir Announces Janssen Decision to Terminate its Simeprevir License Effective June 2018

http://mb.cision.com/Main/652/2410803/764767.pdf Press release (PDF) ...

Read More ...

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)

Best outcomes observed in patients treated with IMBRUVICA at first relapse; these patients maintained PFS for a median of nearly three years ATLANTA and RARITAN, N.J. , Dec. 9, 2017 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced results of a pooled analy...

Read More ...

IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

- Nearly half of all R/R MCL patients in the pooled analysis were able to survive their disease at three years and more than one quarter of patients had no progression in their disease AbbVie Inc. +1 (847) 938-9190 1 North Waukegan Road abbvie.com North Chicago, IL ...

Read More ...

St. Jude gene therapy improves immunity in babies with 'bubble boy' disease

Preliminary findings indicate gene therapy pioneered at St. Jude Children's Research Hospital is safe and effective for babies with a devastating inherited disorder that leaves them with little or no immune protection ...

Read More ...

Bioengineering and Specialized Therapies Yield Results for Rare and Challenging Blood Diseases

Advances in gene therapy, stem cell engineering, and targeted drugs show persistence pays off ATLANTA , Dec. 9, 2017 /PRNewswire-USNewswire/ -- In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta , researchers a...

Read More ...

New Therapies Improve Outlook for Bleeding and Clotting Disorders

Novel drugs and gene therapy show promising results in trials for patients with hemophilia A and cancer ATLANTA , Dec. 9, 2017 /PRNewswire-USNewswire/ -- In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta , re...

Read More ...

ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017

REDWOOD CITY, Calif. , Dec. 9, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today released additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) in non-small cell lung cancer (NSCLC). In 27 NSCLC patients...

Read More ...

IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients

- Follow-up data from RESONATE™-2 suggest long-term benefits of ibrutinib as a first-line therapy in CLL, via the longest patient-reported outcomes to date and a progression-free survival rate of 85 percent ...

Read More ...

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication

Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 Study ...

Read More ...

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Dec. 8, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on December 4, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common ...

Read More ...

New Best Practices, LLC Report Provides Window into Future Trends for Digital Marketing Budget, Staffing and Performance Measurement

CHAPEL HILL, N.C. , Dec. 8, 2017 /PRNewswire/ -- Pharmaceutical and medical device companies are increasingly using digital engagement channels to more effectively communicate with their customers. Unlike many other operational areas of pharma and medical device organizations, the performance ...

Read More ...

Seno Medical Instruments Announces New Data Demonstrating That Imagio™ Opto-Acoustic Breast Imaging System Delivers Critical Diagnostic and Prognostic Information About Tumor Subtypes

- Prospective clinical study presented at the San Antonio Breast Cancer Symposium suggests Imagio findings may help clinicians tailor patient treatment regimens - ...

Read More ...

Verisys Corporation Makes Comparably's 2017 Best Places to Work

Company's Leader Also Recognized as one of '2017 Best CEOs in the United States' ...

Read More ...

QIAGEN to Transfer U.S. Listing of Global Shares to NYSE

GERMANTOWN, Maryland , and HILDEN, Germany , December 8, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it is transferring the U.S. listing of its global shares to the New York Stock Exchange (NYSE) from the NASDAQ Global Market. Click ...

Read More ...

American Diabetes Association® Releases 2018 Standards of Medical Care in Diabetes, with Notable New Recommendations for People with Cardiovascular Disease and Diabetes

Comprehensive recommendations reflect the latest advances in evidence-based research to improve care for millions of people with diabetes ...

Read More ...

Red Cross Provides Shelter and Comfort as 7 Large Wildfires Burn in Southern California

People Urged to Listen to Local Officials and Heed Evacuation Orders ...

Read More ...

Health Canada welcomes comments on release of clinical information on drugs and medical devices

Increased transparency benefits Canadians and the health care system OTTAWA , Dec 8, 2017 /CNW/ - Health Canada is modernizing its approach to disclosing clinical information on drugs and medical devices to support advances in medical science and help improve patient care. Today, Health Cana...

Read More ...
More Press Releases

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store